Excelsior Biopharma (6496) — Capital Reinvestment Ratio
Latest as of June 2025:
3.80x
Excelsior Biopharma (6496) has a Capital Reinvestment Ratio of 3.80x as of June 2025, meaning it reinvests 4% of its operating cash flow (NT$3.80 Million) in capital expenditures (NT$14.44 Million). See Excelsior Biopharma (6496) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
3.80x
Capex / Operating Cash Flow
Operating Cash Flow
NT$3.80 Million
TWD
Capital Expenditures
NT$14.44 Million
TWD
Data as of
Jun 2025
Most recent filing
Excelsior Biopharma Capital Reinvestment Ratio (2017–2022)
This chart tracks Excelsior Biopharma's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Excelsior Biopharma (2017–2022)
Year-by-year Capital Reinvestment Ratio for Excelsior Biopharma from 2017 to 2022. For live market cap and broader valuation context, see Excelsior Biopharma (6496) total market value.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 1.42x | NT$5.49 Million | NT$7.78 Million | ▲ +2652.7% |
| 2021 | 0.05x | NT$55.82 Million | NT$2.88 Million | ▲ +131.1% |
| 2020 | 0.02x | NT$520.81 Million | NT$11.62 Million | ▼ -70.3% |
| 2018 | 0.08x | NT$126.92 Million | NT$9.54 Million | ▲ +45.2% |
| 2017 | 0.05x | NT$349.47 Million | NT$18.10 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow